Market closed
Amicus Therapeutics/$FOLD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Amicus Therapeutics
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Ticker
$FOLD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
499
Website
FOLD Metrics
BasicAdvanced
$2.8B
-
-$0.18
0.61
-
Price and volume
Market cap
$2.8B
Beta
0.61
52-week high
$14.02
52-week low
$8.79
Average daily volume
2.3M
Financial strength
Current ratio
3.394
Quick ratio
2.361
Long term debt to equity
224.272
Total debt to equity
228.629
Interest coverage (TTM)
0.69%
Management effectiveness
Return on assets (TTM)
2.72%
Return on equity (TTM)
-31.68%
Valuation
Price to revenue (TTM)
5.295
Price to book
14.16
Price to tangible book (TTM)
-131.18
Price to free cash flow (TTM)
-74.705
Growth
Revenue change (TTM)
32.29%
Earnings per share change (TTM)
-64.11%
3-year revenue growth (CAGR)
20.03%
3-year earnings per share growth (CAGR)
-41.54%
What the Analysts think about FOLD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Amicus Therapeutics stock.
FOLD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FOLD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FOLD News
AllArticlesVideos
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
Business Wire·4 days ago
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 days ago
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
GlobeNewsWire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amicus Therapeutics stock?
Amicus Therapeutics (FOLD) has a market cap of $2.8B as of February 23, 2025.
What is the P/E ratio for Amicus Therapeutics stock?
The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of February 23, 2025.
Does Amicus Therapeutics stock pay dividends?
No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next Amicus Therapeutics dividend payment date?
Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.
What is the beta indicator for Amicus Therapeutics?
Amicus Therapeutics (FOLD) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.